Immune responses to malignancies

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 2 SUPPL. 2, 2010, Pages

  Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer; effector T cells; immune suppression; immunity; tumor escape

Indexed keywords

AGATOLIMOD; ALPHA FETOPROTEIN; BAGE PROTEIN; CANCER TESTIS ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GAGE PROTEIN; GLYCOPROTEIN GP 100; GLYPICAN 3; INTERLEUKIN 13 RECEPTOR ALPHA2; LAGE PROTEIN; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MONTANIDE ISA 51; NY ESO 1 PROTEIN; ONCOFETAL ANTIGEN; ONCOPROTEIN; PEPTIDE DERIVATIVE; PROTEIN P53; PROTEOCHONDROITIN SULFATE; RAS PROTEIN; SAGE PROTEIN; SURVIVIN; TUMOR ANTIGEN; TYROSINASE RELATED PROTEIN 1; TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOPOTENTIATION; INNATE IMMUNITY; MALIGNANT TRANSFORMATION; MELANOMA; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SOLID TUMOR; SUPPRESSOR CELL; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNITY; IMMUNOTHERAPY; NEOPLASMS; TUMOR ESCAPE;

EID: 76749151403     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.09.045     Document Type: Article

References (96)

1. Romero P., Cerottini J.C., and Speiser D.E. The human T cell response to melanoma antigens. Adv Immunol 92 (2006) 187-224
2. Dunn G.P., Koebel C.M., and Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6 (2006) 836-848
3. Zhang L., Zhou W., Velculescu V.E., Kern S.E., Hruban R.H., Hamilton S.R., et al. Gene expression profiles in normal and cancer cells. Science 276 (1997) 1268-1272
4. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., and Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3 (2002) 991-998
5. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27 (2008) 5904-5912
6. Kornstein M.J., Brooks J.S., and Elder D.E. Immunoperoxidase localization of lymphocyte subsets in the host responses to melanoma and nevi. Cancer Res 43 (1983) 2749-2753
7. Von Kleist S., Berling J., Bohle W., and Wittekind C. Immunohistochemical analysis of lymphocyte subpopulations infiltrating breast carcinomas and benign lesions. Int J Cancer 40 (1987) 18-23
8. Whiteside T.L. Tumor infiltrating lymphocytes in human malignancies. Austin (TX): R.G. Landes Co (1993)
9. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006) 1960-1964
10. Galon J., Fridman W.-H., and Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 67 (2007) 1883-1886
11. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., et al. Effector memory T cells, early metastasis and survival in colorectal cancer. N Engl J Med 353 (2005) 2654-2666
12. Camus M., Tosolini M., Mlecnik B., Pages F., Kirilovsky A., Berger A., et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 69 (2009) 2685-2693
13. Lee P.P., Yee C., Savage P.A., Fong L., Brockstedt D., Weber J.S., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5 (1999) 677-685
14. Pittet M.J., Speiser D.E., Lienard D., Valmore D., Guillaume P., Dutoit V., et al. Expansion and functional maturation of human tumor antigen-specific CD8 + T cells after vaccination with antigenic peptide. Clin Cancer Res 7 (2001) 796s-803s
15. 264-272 peptide in the circulations of patients with head and neck cancer. Cancer Res 62 (2002) 3521-3529
16. Sahin U., Tureci O., and Pfreundschuh M. Serologic identification of human tumor antigens. Curr Opin Immunol 9 (1997) 709-716
17. Matzinger P. An innate sense of danger. Semin Immunol 10 (1998) 399-415
18. Szczepanski M.J., Czystowska M., Szajnik M., Harasymczuk M., Boyiadzis M., Kruk-Zagajewska A., et al. Triggering of toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 69 (2009) 3105-3113
19. Uematsu S., and Akira S. Toll-like receptors and innate immunity. J Mol Med 84 (2006) 712-725
20. Hollstein M., Sidransky D., Vogelstein B., and Harris C. p53 mutations in human cancers. Science 253 (1991) 49-53
21. Provinciali M. Immunosenescence and cancer vaccines. Cancer Immunol Immunother 58 (2009) 1959-1967
22. Ferrone S., and Whiteside T.L. Tumor microenvironment and immune escape. Surg Oncol Clin North Am 16 (2007) 755-774
23. Ferris R.L., Whiteside T.L., and Ferrone S. Immune escape associated with functional defects in antigen processing machinery in head and neck cancer. Clin Cancer Res 12 (2006) 3890-3895
24. Stickel J.S., Weinzieri A.O., Hillen N., Drews O., Schuler M.M., Hennenlotter J., et al. HLA ligand profile of primary renal cell carcinoma maintained in metastases. Cancer Immunol Immunother 58 (2009) 1407-1417
25. Fearon D.T., and Locksley R.M. The instructive role of innate immunity in the acquired immune response. Science 272 (1996) 50-54
26. Irving B.A., and Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64 (1991) 891-901
27. Greenwald R.J., Freeman G.J., and Sharpe A.H. The B7 family revisited. Annu Rev Immunol 23 (2005) 515-548
28. Kalinski P., Hilkens C.M., Wierenga E.A., and Kapsenberg M.L. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 20 (1999) 561-567
29. Whiteside T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic interventions. Semin Cancer Biol 16 (2006) 3-15
30. Reichert T.E., Strauss L., Wagner E.M., Gooding W., and Whiteside T.L. Signaling abnormalities and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 8 (2002) 3137-3145
31. Uzzo R.G., Clark P.E., Rayman P., Bloom T., Rybicki L., Novick A.C., et al. Alterations in NFκB activation in T lymphocytes of patients with renal cell carcinoma. J Natl Cancer Inst 91 (1999) 718-721
32. Reichert T.E., Rabinowich H., Johnson J.T., and Whiteside T.L. Human immune cells in the tumor microenvironment: mechanisms responsible for signaling and functional defects. J Immunother 21 (1998) 295-306
33. Cavallo F., Offringa R., van der Burg S.H., Forni G., and Melief C.J. Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 90 (2006) 175-213
34. Lollini P.L., De Giovanni C., Pannellini T., Cavallo F., Forni G., and Nanni P. Cancer immunoprevention. Future Oncol 1 (2005) 57-66
35. Pannellini T., Forni G., and Musiani P. Immunobiology of her-2/neu transgenic mice. Breast Dis 20 (2004) 33-42
36. Parmiani G., De Filippo A., Novellino L., and Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 178 (2007) 1975-1979
37. Finn O.J., Binder R.J., Brickner A.G., Butterfield L.H., Ferris R.L., Kalinski P., et al. Human tumor antigens as targets of immunosurveillance and candidates for cancer vaccines. In: Gires O., and Seliger B. (Eds). Tumor-associated antigens: identification, characterization, and clinical applications (2009), Wiley-VCH, Weinheim (Germany) 23-43
38. Cheever M., Allison J.P., Ferris A.S., Finn O.J., Hastings B.M., Hecht T.T., et al. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res 15 (2009) 5323-5337
39. Smyth M.J., Dunn G.P., and Schreiber R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 90 (2006) 1-50
40. Jager E., Karbach J., Gnjatic S., Neumann A., Bender A., Valmori D., et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A 103 (2006) 14453-14458
41. Whiteside T.L. The local tumor microenvironment. In: Kaufmann H., and Wolchok J.D. (Eds). General principles of tumor immunotherapy: basic and clinical applications of tumor immunology (2007), Springer, New York 145-167
42. June C.H. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117 (2007) 1466-1476
43. Bergmann C., Strauss L., Zeidler R., Lang S., and Whiteside T.L. Expansion of human T regulatory type 1 cells in the microenvironment of COX-2-overexpressing head and neck squamous cell carcinoma. Cancer Res 67 (2007) 8865-8873
44. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., et al. Regulatory CD4 + CD25 + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61 (2001) 4766-4772
45. highFOXP3 + T cells secreting IL-10 and TGF-β1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13 (2007) 4345-4354
46. Mandapathil M., Szczepanski M.J., Szajnik M., Ren J., Lenzner D.E., Jackson E.K., et al. Increased ectonucleotidase expression and activity in Treg of patients with head and neck cancer. Clin Cancer Res 15 (2009) 6348-6357
47. Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor microenvironment. Blood 114 (2009) 1141-1149
48. Martinez O., Sica A., Mantovani A., and Locati M. Macrophage activation and polarization. Front Biosci 13 (2008) 453-461
49. Leek R.D., Lewis C.E., Whitehouse R., Geenall M., Clarke J., and Harris A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56 (1996) 4625-4629
50. Serafini P., Borello I., and Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16 (2006) 53-65
51. Ochoa A.C., Zea A.H., Hernandez C., and Rodríguez P.C. Arginase, prostaglandins, and myeloid supressor cells in renal cell carcinoma. Clin Cancer Res 13 (2007) 721s-726s
52. Diebold S.S. Determination of T-cell fate by dendritic cells. Immunol Cell Biol 86 (2008) 389-397
53. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2 (1996) 1096-1103
54. Shurin G.V., Shurin M.R., Bykovskaja S., Shogan J., Lotze M.T., and Barksdale E.M. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 61 (2001) 363-369
55. Reichert T.E., Scheuer C., Day R., Wagner W., and Whiteside T.L. The number of intratumoral dendritic cells and ζ-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 91 (2001) 2136-2147
56. Murphy G.F., Radu A., Kaminer M., and Berg D. Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy. J Invest Dermatol 100 suppl (1993) 335S-341S
57. Lanier L.L. Natural killer cell receptor signaling. Curr Opin Immunol 15 (2003) 308-314
58. Chang C.C., Campoli M., and Ferrone S. Classical and nonclassical HLA class I antigen and NK cell-activating ligand changes in malignant cells: current challenges and future direction. Adv Cancer Res 93 (2005) 189-234
59. Kelly J.M., Darcy P.K., Markby J.L., Godfrey D.I., Takeda K., Yagitab H., et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 3 (2002) 83-90
60. Coronella J.A., Spier C., Welch M., Trevor K.T., Stopeck A.T., Villar H., et al. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol 169 (2002) 1829-1836
61. Denko N.C., Fontana L.A., Hudson K.M., Sutphin P.D., Raychaudhuri S., Altman R., et al. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22 (2003) 5907-5914
62. Aller M.A., Arias J.L., Nava M.P., and Arias J. Posttraumatic inflammation is a complex response based on the pathological expression of the nervous, immune and endocrine function systems. Exp Biol Med 229 (2004) 170-181
63. Dworacki G., Meidenbauer N., Kuss I., Hoffmann T.K., Gooding M.S., Lotze M., et al. Decrease ζ chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 7 suppl (2001) 947s-957s
64. Finke J.H., Rayman P., George R., Tannenbaum C.S., Kolenko V., Uzzo R., et al. Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor kappa B suppression. Clin Cancer Res 7 suppl (2001) 940s-946s
65. Whiteside T.L. Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 12 (2001) 43-50
66. Kuss I., Schaefer C., Godfrey T.E., Ferris R.L., Harris J., Gooding W., et al. Recent thymic emigrants and subsets of naïve and memory T cells in the circulation of patients with head and neck cancer. Clin Immunol 116 (2005) 27-36
67. Kim W.-J., Tsukishiro T., Johnson J.T., and Whiteside T.L. Expression of pro- and anti-apoptotic proteins in circulating CD8 + T cells of patients with squamous cell carcinoma of the head and neck (SCCHN). Clin Cancer Res 10 (2004) 5101-5110
68. Kim J.-W., Ferris R.L., and Whiteside T.L. Chemokine receptor 7 (CCR7) expression and protection of circulating CD8 + T lymphocytes from apoptosis. Clin Cancer Res 11 (2005) 7901-7910
69. Kuss I., Saito T., Johnson J.T., and Whiteside T.L. Clinical significance of decreased ζ chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 5 (1999) 329-334
70. Hoffmann T.K., Dworacki G., Meidenbauer N., Gooding W., Johnson J.T., and Whiteside T.L. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8 (2002) 2553-2562
71. Whiteside T.L. The role of death receptor ligands in shaping tumor microenvironment. Immunol Invest 36 (2007) 25-46
72. O'Connell J., O'Sullivan G.D., Collins J.K., and Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184 (1996) 1075-1082
73. Whiteside T.L. Lymphocyte homeostasis and the antitumor immune response. Exp Rev Clin Immunol 1 (2006) 369-378
74. Albers A.E., Visus C., Tsukishiro T., Ferris R.L., Gooding W., Whiteside T.L., et al. Alterations in the T-cell receptor variable β gene-restricted profile of CD8 + T lymphocytes in the peripheral circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 12 (2006) 2394-2403
75. Whiteside T.L. Immune effector cells in the tumor microenvironment: their role in regulation of tumor progression. In: Yefenof E. (Ed). Innate and adaptive responses in the tumor microenvironment (2008), Springer, New York 1-34
76. Vujanovic N.L., Nagashima S., Herberman R.B., and Whiteside T.L. Non-secretory apoptotic killing by human natural killer cells. J Immunol 157 (1996) 1117-1126
77. Whiteside T.L., Vujanovic N.L., and Herberman R.B. Natural killer cells and tumor therapy. Curr. Topics Microbiol Immunol 230 (1998) 221-244
78. Hansson M., Asea A., Ericsson U., Hermodsson S., and Hellstrand K. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol 156 (1996) 42-47
79. Whiteside T.L. Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy. Vaccine 20 (2002) A46-A51
80. Smyth M.F., and Godfrey D.I. NKT cells and tumor immunity-a double-edged sword. Nat Immunol 1 (2000) 459-460
81. Gershon R.K. A disquisition on suppressor T cells. Transpl Rev 26 (1975) 170-185
82. Bluestone J.A., and Abbas A.K. Natural versus adaptive regulatory T cells. Nat Rev 3 (2003) 253-257
83. Bergmann C., Strauss L., Wang Y., Szczepanski M.J., Lang S., Johnson J.T., et al. T regulatory type 1 cells (Tr1) in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14 (2008) 3706-3715
84. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma foster immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
85. Salama P., Phillips M., Grieu P., Morris M., Zeps N., Joseph D., et al. Tumor-infiltrating FOXP3 + T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27 (2008) 186-192
86. Martin-Orozco N., and Dong C. The IL-17/IL23 axis of inflammation in cancer: friend or foe?. Curr Opin Investig Drugs 10 (2009) 543-549
87. Voo K.S., Wang Y.-H., Santori F.R., Boggiano C., Yi-H W., Arima K., et al. Identification of IL-17-producing FOXP+ regulatory T cells in humans. Proc Natl Acad Sci U S A 106 (2009) 4793-4798
88. Munn D.H., and Mellor A.L. Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest 117 (2007) 1147-1154
89. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90 (1993) 3539-3543
90. Filipazzi F., Valenti R., Huber V., Pilla L., Canese P., Iero M., et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25 (2007) 2546-2553
91. Azuma T., Yao S., Zhu G., Flies S.J., and Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111 (2008) 3635-3643
92. Blank C., and Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56 (2007) 739-745
93. Wang W., Lau R., Yu D., Zhu W., Korman A., and Weber J. PD1 blockade reverses the suppression on melanoma antigen-specific CTL by CD4 + CD25hi regulatory T cells. Int Immunol 21 (2009) 1065-1077
94. Hirano F., Kaneko K., Tamura H., Dong H., Wang S., Ichikawa M., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65 (2005) 1089-1096
95. Wang L., Yi T., Kortylewski M., Pardoll D.M., Zeng D., and Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signalling pathway. J Exp Med 206 (2009) 1457-1464
96. Finn O.J. Cancer immunology. N Engl J Med 358 (2008) 2704-2715